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A subset of the population receiving opioids for the treatment of acute and chronic clinical
pain develops a paradoxical increase in pain sensitivity known as opioid-induced hyperal-
gesia. Given that opioid analgesics are one of few treatments available against clinical pain,
it is critical to determine the key molecular mechanisms that drive opioid-induced hyperalge-
sia in order to reduce its prevalence. Recent evidence implicates a splice variant of the mu
opioid receptor known as MOR-1K in the emergence of opioid-induced hyperalgesia.
Results from human genetic association and cell signaling studies demonstrate that MOR-
1K contributes to decreased opioid analgesic responses and produces increased cellular
activity viaGs signaling. Here, we conducted the first study to directly test the role of MOR-
1K in opioid-induced hyperalgesia.
Methods and Results
In order to examine the role of MOR-1K in opioid-induced hyperalgesia, we first assessed
pain responses to mechanical and thermal stimuli prior to, during, and following chronic
morphine administration. Results show that genetically diverse mouse strains (C57BL/6J,
129S6, and CXB7/ByJ) exhibited different morphine response profiles with corresponding
changes inMOR-1K gene expression patterns. The 129S6 mice exhibited an analgesic
response correlating to a measured decrease inMOR-1K gene expression levels, while
CXB7/ByJ mice exhibited a hyperalgesic response correlating to a measured increase in
MOR-1K gene expression levels. Furthermore, knockdown ofMOR-1K in CXB7/ByJ mice
via chronic intrathecal siRNA administration not only prevented the development of opioid-
induced hyperalgesia, but also unmasked morphine analgesia.
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Conclusions
These findings suggest that MOR-1K is likely a necessary contributor to the development of
opioid-induced hyperalgesia. With further research, MOR-1K could be exploited as a target
for antagonists that reduce or prevent opioid-induced hyperalgesia.
Introduction
Opioids are the most commonly used treatment for moderate to severe clinical pain, with 259
million prescriptions written within the United States in 2012 [1]. Paradoxically, opioids can
also produce pain. This abnormal phenomenon, known as opioid-induced hyperalgesia (OIH),
is defined by increased pain sensitivity that occurs following acute or chronic opioid adminis-
tration and is distinct from the originally reported pain [2]. OIH is especially prevalent in indi-
viduals who suffer from chronic pain, affecting up to 30% of individuals that use opioids to
treat their pain [2,3]. OIH is often confused with tolerance to and withdrawal from the admin-
istered opioid treatment. Unlike opioid tolerance, which is a decreased analgesic efficacy of the
same opioid dose over time, OIH can manifest at any opioid dose during acute or chronic
administration [4]. Unlike opioid withdrawal, which is characterized by a hyperalgesic
response following abrupt opioid cessation, OIH manifests during as well as following opioid
administration [4]. Mistaking OIH for opioid tolerance or withdrawal results in inadequate
treatment options that may intensify the reported pain. Thus, it is critical to identify the molec-
ular mechanisms underlying OIH.
Accumulating evidence indicates that MOR-1K, a functional splice variant of the canonical
mu opioid receptor (MOR-1), may contribute to the emergence of OIH. MOR-1K is a trun-
cated six transmembrane g-protein coupled receptor (GPCR) lacking a N-terminus transmem-
brane due to the absence of exon 1 within its mRNA transcript [5]. Replacing exon 1 are exon
11, which provides an alternative translation start site in several MOR-1 splice variants, and
exon 13, which is unique to theMOR-1K transcript. The MOR-1 transcript, which encom-
passes exons that encode for MOR-1K, is highly conserved across species, with a 91% nucleo-
tide sequence homology between human and mouse. Results from a human genetic association
study demonstrated that a single nucleotide polymorphism within exon 13 of the human
MOR-1K transcript is associated with increased pain sensitivity and blunted morphine efficacy
[6]. Subsequent in vitro studies demonstrated that MOR-1K exhibits signaling properties dis-
tinct from its parent receptor MOR-1. MOR-1 utilizes Gi/o protein to inhibit cyclic adenosine
monophosphate (cAMP) levels and intracellular calcium levels to produce cellular inhibition
of pronociceptive cells. In contrast, MOR-1K couples to Gs protein, leading to increased cAMP
production and intracellular calcium levels, thus promoting cellular excitation [7]. Previous
studies have shown that Gs-dependent increases in intracellular calcium via cAMP production
and protein kinase A activation play a critical role in central sensitization [8] and the develop-
ment of inflammatory, neuropathic, and functional pain [9]. The utilization of Gs signaling by
MOR-1K suggests that the receptor may also contribute to central sensitization associated with
OIH.
Given the receptor’s genetic association with increased pain sensitivity and its excitatory sig-
naling profile, we hypothesize MOR-1K may contribute to OIH in genetically susceptible indi-
viduals. Here, we evaluate MOR-1K in the development of OIH using three genetically diverse
mouse strains alongside small interfering RNA (siRNA) knockdown ofMOR-1K. Our results
demonstrate that OIH is associated with increasedMOR-1K gene expression levels in a strain-
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specific manner. Disrupting the increase inMOR-1K gene expression levels via chronic intra-
thecal (i.t.) siRNA administration not only hinders the development of OIH, but also increases
morphine analgesic efficacy. Collectively, these findings demonstrate that MOR-1K is likely a
key contributor to OIH.
Materials & Methods
Ethical Statement
All procedures within this study were approved by the University of North Carolina Animal
Care and Use Committee (permit number: 12–319) and adhered to the guidelines of the Com-
mittee for Research and Ethical Issues of the International Association of the Study of Pain
(http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1217). All surgeries were
performed under isofluorane anesthesia, and all efforts were made to minimize suffering.
Animals
Male and female C57BL/6J (http://jaxmice.jax.org/strain/000664.html) and CXB7/ByJ (http://
jaxmice.jax.org/strain/000357.html) mice were obtained from Jackson Labs (Bar Harbor, ME)
while 129S6 (http://www.taconic.com/129SVE) mice were obtained from Taconic (German-
town, NY). All mice were 8–12 weeks old, weighed 20–30 g, were maintained under 12-hour
light/dark cycle, and were fed ad libitum.
Drugs and Chemicals
Morphine sulfate (Sigma, MO) was dissolved in 0.9% sterile saline (Hospira, IL). Doses of
10 mg/kg, 20 mg/kg, or 40 mg/kg were administered via subcutaneous (s.c.) injection in a vol-
ume determined by animal weight (1μl/g). Fluorescein-tagged exon 13-antisense siRNA [5’-
UCA GUC UUU AUC AGC UCA CCG CCA-3’] or fluorescein-tagged exon 13-sense siRNA
(Midland Certified Reagent Co., OH) [5’-AGU CAG AAA UAG UCG AGU GGC GGU-3’] in
artificial cerebrospinal fluid was administered at a rate of 0.5μl/hr; 0.291μg/hr/day for a dura-
tion of 7 days via Alzet osmotic mini-pump (Durect, CA) connected to an i.t. catheter (Durect,
CA). Previous studies have successfully administered siRNA in this fashion as well [10–12].
Sense siRNA was chosen as a negative control as it is related to the target mRNA sequence of
interest but does not affect target mRNA expression [13].
Experimental Design
Experiment 1: The effects of chronic morphine administration on pain behavior and
gene expression. Prior to chronic morphine administration, C57BL/6J, CXB7/ByJ, and 129S6
mice (N = 96; 8 males and 8 females per experimental condition) were assessed for baseline
responses to mechanical and thermal heat stimuli. Following baseline assessments, mice
received morphine similar to the murine OIH protocol described by Liang et al [14]. Briefly,
mice received vehicle (sterile saline) or escalating doses of morphine (10 mg/kg, 20 mg/kg,
20 mg/kg, and 40 mg/kg) twice daily (8am and 6pm) via s.c. injection on days 1, 2, 3, and 4,
respectively. Behavioral responses were evaluated prior to and immediately following the 8am
injection on days 1–4 and at 8am on days 5–7. Gene expression levels were measured in tissues
collected from separate groups of C57BL/6J, 129S6, and CXB7/ByJ mice (N = 84; 3–4 males
and 3–4 females per experimental condition) sacrificed on day 0, on days 1 or 4 following the
8am injection, or on day 5 at 8am.
Experiment 2: The effects of MOR-1K exon 13 siRNA knockdown on OIH and MOR-1K
gene expression. Prior to chronic morphine administration, CXB7/ByJ mice (N = 48; 8 males
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and 8 females per experimental condition) were assessed for baseline responses to mechanical
stimuli. Following baseline assessments, mice underwent surgery for chronic i.t. administration
of antisense exon 13 siRNA or sense exon 13 siRNA. Mice were anesthetized with 5% isofluor-
ane and maintained at 2–3% isofluorane during i.t. catheter implantation, modified from
Yaksh and Rudy protocol [15]. A separate group of mice also underwent surgery for a sham
procedure. The sham procedure, involving skin incision and muscle dissection without break-
age of the arachnoid membrane to cause leakage of cerebral spinal fluid, was deemed appropri-
ate to control for any postoperative pain. One day following surgery, mice from antisense,
sense, and sham conditions began to receive either vehicle (sterile saline) or escalating doses of
morphine as described above.MOR-1K gene expression levels were measured in tissues col-
lected from separate groups of CXB7/ByJ mice (N = 84; 3–4 males and 3–4 females per experi-
mental condition) sacrificed on day 0, on days 1 or 4 following the 8am injection, or on day
5 at 8am.
Behavior
Assessment of PawWithdrawal Threshold, Mechanical Allodynia, and Mechanical
Hyperalgesia. Mice were handled and habituated to the testing environment for 4 days prior
to baseline assessments. On test days, mice were placed in plexiglass cages positioned over an
elevated wire mesh platform and habituated to the environment for 20 minutes. Paw with-
drawal threshold in response to a series of 9 von Frey filaments (with bending forces of 0.03,
0.07, 0.17, 0.40, 0.70, 1.19, 1.50, 2.05, 3.63g; Stoeling, IL) was assessed using the “up-down”
method [16], starting with a filament with bending force of 0.70 g. In the absence of a paw
withdrawal response, an incrementally stronger filament was presented and in the event of a
paw withdrawal, an incrementally weaker filament was presented. After the initial response
threshold was crossed, this procedure was repeated in order to obtain a total of six responses in
the immediate vicinity of the threshold. The pattern of withdrawals and absence of withdrawals
were noted together with the terminal filament used in the series of six responses. The 50% of
the paw withdrawal threshold is calculated as (10[Xf
+kδ])/10,000, where Xf = value (in log units)
of the final von Frey hair used; k = tabular value of pattern of positive (X) and negative (O)
responses, and δ = mean difference (in log units) between stimuli. Mechanical allodynia was
assessed by presenting a filament with bending force of 0.40 g to the hind paw 10 times for a
duration of 1 s with an inter-stimulus interval of 1 s. A significant increase in the percentage
frequency of paw withdrawal ([# of paw withdrawals/10] x 100) was defined as mechanical
allodynia. Mechanical hyperalgesia was assessed in the same manner, using a filament with a
bending force of 1.50 g.
Assessment of Thermal Heat Hyperalgesia. Thermal heat hyperalgesia was evaluated
using the hot plate method [17]. Mice were placed on a hot plate (Columbus Instruments, OH)
maintained at a temperature of 51.5°C for one minute. Each session was videotaped and the
total number of aversive responses (paw licks, paw flicks, and jumps) was measured.
Assessment of Gene Expression Levels
Discrete brain and spinal cord samples were collected on days 0, on day 1 and 4 following the
8am morphine administration, and on day 5, 24 hours following morphine cessation. Total
RNA from discrete brain regions (medulla, pons, periaqueductal grey, thalamus, hypothala-
mus, striatum, nucleus accumbens, and frontal lobe), and spinal cord was purified using 1mL
TRIzol (Life Technologies, NY) for each tissue sample. Samples were immediately homoge-
nized using a Pro200 homogenizer (Pro Scientific, CT) or Precellys 24 Homogenizer (Bertin
Technologies, France) and all subsequent RNA purification steps were performed according to
MOR-1K Contributes to OIH
PLOSONE | DOI:10.1371/journal.pone.0135711 August 13, 2015 4 / 16
the TRIzol manufacturer recommendations. Purified RNA samples were treated with TURBO
DNA-free (Life Technologies, NY) per manufacturer protocol and concentrations were deter-
mined using a Nanodrop-1000 (Thermo Scientific, DE) and reverse transcribed using Tran-
scriptor First Strand cDNA Synthesis kit (Roche, Switzerland) where necessary. Fast Start
Universal SYBR Green Master with Rox (Roche, Switzerland) or Power SYBR Green RNA-to-
CT 1-Step (Life Technologies, NY) were respectively used per manufacturer protocols to
amplify cDNA and RNA, per manufacturer protocols. A 7900HT Fast Real-Time PCR system
(Life Technologies, NY) and a StepOnePlus Real-Time PCR system (Life Technologies, NY)
were respectively used for measuring cDNA or RNA transcripts amplification. The following
primers were used for the detection of the following exon-11 containing MOR-1 splice vari-
ants: MOR-1K forward (TCCCCTCTTGAGTGTGACTAATGTC) and reverse (GCCAGAG
CAAGGTTGAAAATG); MOR-1L forward (CAGAGCAAGGTTGAAAATGTAGATG) and
reverse (AAATCAAAATAGAAAATGGGCTAAGG); MOR-1T forward (GAGCCACATG
GAATTGCCTCTGTA) and reverse (GCATCTGCCAGAGCAAGGTTGAAA); forward
(GGGCCGATGATGGAAGCTTTCTCTAA) and reverse (GCATCTGCCAGAGCAAGGTT
GAAA) primers for splice variants that contain exons 11 and 2. Expression of the target genes
was normalized to housekeeping genes RPL7 [forward (TCAATGGAGTAAGCCCAAAG)
and reverse (CAAGAGACCGAGCAATCAA)] or GAPDH [forward (TGAAGGTCGGAGT
CAACGGATTTGGT) and reverse (CATGTGGGCCATGAGGTCCACCAC)] using the
2(-ΔΔCT) method. All primers were purchased from Integrated DNA Technologies (CA).
Statistical Analysis
Baseline responses for paw withdrawal threshold, mechanical allodynia, and mechanical hyper-
algesia for each strain were analyzed using one-way ANOVA followed by Bonferroni correc-
tion. Subsequent behavioral responses following morphine administration were then analyzed
using two-way repeated measures ANOVA with Bonferroni correction for multiple compari-
sons. Gene expression was analyzed using a linear mixed model, where the log (10) gene
expression of each tissue-replicate assay was the dependent variable and strain was the random
effect. For all tests, the criterion for statistical significance level was p<0.05. Statistical analyses
were performed using Prism (GraphPad Software, CA)
Results
Strains demonstrate divergent baseline pain profiles
First, we sought to establish baseline pain responses to mechanical stimuli in C57BL/6J, 129S6,
and CXB7/ByJ mice. The C57BL/6J strain was chosen as it is the most studied classic inbred
strain, the 129S6 strain was chosen because of its reported resistance to opioid tolerance [18],
and the CXB7/ByJ strain was chosen because of its reported decrease inMOR-1 gene expres-
sion [19]. For all three strains, male and female mice demonstrated similar behavioral differ-
ences to mechanical and thermal heat stimuli (S1 Fig); hence all behavioral data was pooled
together for analysis.
Our results showed that the strains exhibited baseline differences in mechanical (Fig 1A,
F(2,43) = 20.56, p<0.0001; Fig 1B, F(2,43) = 43.77, p<0.0001), and thermal heat pain sensitivity
(Fig 1C; F(2,43 = 10.64, p = 0.0002). Compared to the classic C57BL/6J inbred strain, 129S6
mice were less pain sensitive, exhibiting higher paw withdrawal thresholds and fewer responses
to a noxious mechanical stimulus or to thermal heat. In contrast, CXB7/ByJ mice were more
pain sensitive, exhibiting lower paw withdrawal thresholds and increased responses to innocu-
ous mechanical or thermal heat stimuli.
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Fig 1. Strains exhibit divergent behavioral responses to mechanical stimuli at baseline.Compared to
C57BL/6J mice, 129S6, and CXB7/ByJ mice exhibit differences in (A) paw withdrawal threshold, (B) the
number of responses to repeated presentation of a noxious mechanical stimulus sensitivity, and (C) the
number of responses to continuous thermal heat.N = 15-16/group. Data expressed as mean ± SEM.
***p<0.001, **p<0.01, *p<0.05 different from C57BL/6J. ###p<0.001 different from 129S6.
doi:10.1371/journal.pone.0135711.g001
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Strains demonstrate divergent pain profiles in a chronic morphine
administration paradigm
Next, we sought to examine the strains’ pain responses following morphine administration
using a modified murine paradigm for OIH [14]. We assessed behavioral responses to mechan-
ical and thermal heat stimuli on days 1–4 during chronic morphine administration and after
morphine cessation on days 5–7 (Fig 2, S2 Fig). When examining percent change from baseline
responses, C57BL/6J, 129S6, and CXB7/ByJ mice exhibited differences in paw withdrawal
thresholds over time (Fig 2B; F(18,430) = 45.38, p<0.0001). C57BL/6J mice showed robust anal-
gesia following morphine administration on days 1–4, then developed allodynia on day 4 prior
to morphine administration and on days 5 and 6 following morphine cessation. When com-
pared to C57BL/6J mice, 129S6 mice also showed analgesia following morphine administration
on days 1–4, albeit to a lesser degree than C57BL/6J mice, however failed to develop allodynia
at later time points (p<0.001). In contrast, CXB7/ByJ mice failed to show analgesia following
morphine administration on days 1–4, but did develop allodynia prior to morphine adminis-
tration on days 3 and 4 and following morphine cessation on days 5 and 6 (p<0.001). Of note,
CXB7/ByJ mice also exhibited allodynia following morphine administration on day 3
(p<0.001).
Strains also exhibited differences in their response to repeated presentation of a normally
innocuous punctate mechanical stimulus over time (Fig 2C; F(18,430) = 32.88, p<0.0001).
C57BL/6J mice developed mechanical allodynia prior to morphine administration on day 4
and following morphine cessation on days 5 and 6. Consistent with the paw withdrawal thresh-
old data, 129S6 mice failed to develop mechanical allodynia. CXB7/ByJ mice, however, demon-
strated the highest degree of mechanical allodynia, evident prior to morphine administration
on days 3 and 4 and following morphine cessation on days 5–7 (p<0.001).
Similarly, strains exhibited differences in their response to repeated presentation of a nor-
mally noxious punctate mechanical stimulus over time (Fig 2D; F(18,430) = 15.19, p<0.0001).
C57BL/6J mice showed analgesia following morphine administration on days 1–4, then devel-
oped mechanical hyperalgesia prior to morphine administration on days 3 and 4 as well as fol-
lowing morphine cessation on days 5–7. 129S6 mice exhibited analgesia following morphine
administration on days 1–4 (p<0.001), however failed to develop mechanical hyperalgesia at
later time points. In contrast to the other strains, CXB7/ByJ mice failed to show analgesia fol-
lowing morphine administration, but did develop mechanical hyperalgesia prior to morphine
administration on days 3 and 4 as well as following morphine cessation on days 5 and 6
(p<0.001). Consistent with their changes in mechanical allodynia, CXB7/ByJ mice also exhib-
ited mechanical hyperalgesia following morphine administration on day 3 (p<0.001). When
assessed for behavioral responses to mechanical stimuli, saline treated controls did not exhibit
any changes in paw withdrawal threshold or demonstrate mechanical allodynia or hyperalgesia
(S3 Fig).
Finally, strains differed over time with respect to their response to thermal heat (Fig 2E;
F(18,430) = 3.906, p<0.0001). When compared to 129S6 mice, C57BL/6J mice developed thermal
heat hyperalgesia starting on day 2 prior morphine administration and following morphine
cessation (p<0.001). CXB7/ByJ mice also developed develop thermal heat hyperalgesia on day
2 and 4 prior to morphine administration and following morphine cessation.
MOR-1K gene expression levels parallel OIH profiles
To determine the relationship between OIH pain profiles andMOR-1K gene expression, spinal
cord and discrete brain tissues were collected from separate groups of mice at times points cor-
responding to maximal analgesia and hyperalgesia. Changes inMOR-1K gene expression levels
MOR-1K Contributes to OIH
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Fig 2. Strains exhibit divergent morphine-dependent analgesic and allodynic/hyperalgesic profiles with corresponding changes inMOR-1K gene
expression. (A) A timeline of chronic morphine administration and the assessments of pain behavior and gene expression are shown. (B-E) Compared to
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across the discrete brain and spinal cord tissues were not significantly different, and thus were
normalized and pooled together (S4–S6 Figs). C57BL/6J, 129S6, and CXB7/ByJ mice exhibited
divergentMOR-1K gene expression levels that paralleled their behavioral profiles (Fig 2F;
p = 0.011). Compared to C57BL/6J mice, 129S6 mice demonstrated decreasedMOR-1K gene
expression levels on days 1 and 4 (p<0.05), in line with their analgesic responses. In contrast,
CXB7/ByJ mice demonstrated increasedMOR-1K gene expression levels on day 4 (p<0.05), in
line with their hyperalgesic responses. Interestingly,MOR-1K gene expression levels for both
129S6 and CXB7/ByJ mice returned to near-baseline levels following the cessation of morphine
treatment on day 5, suggesting that the observed differences were indeed morphine-dependent.
To determine the potential involvement of other MOR-1 splice variants, we measured gene
expression levels of other exon-11 containing splice variants (MOR-1G, MOR-1H, MOR-1I,
MOR-1J, MOR-1L, MOR-1M, MOR-1N and MOR-1T). The splice variants did not exhibit sig-
nificant changes in gene expression levels due to morphine administration (S7 Fig).
Sustained delivery ofMOR-1K exon 13 antisense siRNA prevents OIH
The observed correlation between strain-specific pain profiles andMOR-1K gene expression
levels suggests that MOR-1K contributes to OIH in genetically susceptible mice. To determine
whether MOR-1K is required for the development of OIH in CXB7/ByJ mice, we employed
siRNA knockdown. Male and female CXB7/ByJ mice demonstrated similar behavioral pheno-
types (S8 Fig); thus, all behavioral data was pooled together for analysis. Within the OIH
murine paradigm, we found that sustained i.t. delivery of exon 13 antisense siRNA prevented
the development of mechanical allodynia (Fig 3B; F(2,189) = 24.69, p<0.0001, Fig 3C; F(2,189) =
37.63, p<0.0001) and mechanical hyperalgesia (Fig 3D; F(2,189) = 54.92, p<0.0001). In contrast,
sustained administration of exon 13 sense siRNA or sham surgery did not prevent the develop-
ment of mechanical pain sensitivity. Of note, we also found that sustained i.t. delivery of the
antisense siRNA unmasked morphine analgesia in CXB7/ByJ mice not observed in sense and
sham mice or saline-treated controls (S9 and S10 Figs) A possible concern with sustained i.t.
delivery is the development of inflammation and gliosis in the spinal cord in proximity with
the catheter tip [20,21], and its effects on behavioral assessment. Given that CXB7/ByJ mice
receiving sense siRNA and sham surgery displayed similar behavioral responses throughout
testing, we believe that the use of i.t. catheters for sustained siRNA delivery did not impact the
behavioral assessment of OIH.
Sustained delivery of MOR-1K exon 13 antisense siRNA decreases
MOR-1K gene expression levels
Finally, we evaluated the efficacy of chronic siRNA administration to suppressMOR-1K gene
expression levels in CXB7/ByJ mice. Given that siRNA was administered intrathecally, we
examinedMOR-1K gene expression within the spinal cord. As predicted, sustained i.t. delivery
of antisense siRNA prevented the increase ofMOR-1K gene expression levels in the spinal cord
(Fig 3F; F(1,11) = 29.05, p = 0.0002). In contrast, sustained delivery of sense siRNA failed to
C57BL/6J, 129S6 mice exhibit increased paw withdrawal thresholds and fail to develop allodynia or hyperalgesia. In contrast, CXB7/ByJ exhibit decreased
paw withdrawal thresholds and increased allodynia and hyperalgesia. (F) 129S6 mice exhibit decreasedMOR-1K gene expression levels on days 1 and 4,
corresponding to their analgesic behavioral profile. In contrast, CXB7/ByJ mice exhibit increasedMOR-1K gene expression levels on day 4, corresponding to
their hyperalgesic behavioral profile. For behavioral graphs, blue background indicates a decrease in pain sensitivity (analgesia), and red background
indicates an increase in pain sensitivity (allodynia/hyperalgesia). Panels B-E: N = 15-16/group. Data expressed as mean ± SEM. ***p<0.001, **p<0.01,
*p<0.05 different from C57BL/6J. ### p<0.001, ##p<0.01, #p<0.05 different from 129S6. Panel F: N = 7/group. Data expressed as means ± SEM. *p<0.05
different from baseline.
doi:10.1371/journal.pone.0135711.g002
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block increases inMOR-1K gene expression levels. These findings suggest that MOR-1K
located in spinal sites is necessary for the development of OIH.
Fig 3. CXB7/ByJ mice treated with exon 13 antisense siRNA fail to develop OIH. (A) A timeline of sustained i.t. siRNA delivery, chronic morphine
administration, and assessments of pain behavior and gene expression is shown. CXB7/ByJ mice receiving antisense siRNA exhibit analgesia following
morphine administration and cessation, and fail to exhibit (B) decreased paw withdrawal thresholds, or increased responses to (C) repeated presentation of
an innocuous or (D) noxious mechanical stimulus. In contrast, mice receiving sense siRNA or sham exhibited analgesia following morphine administration,
which was then followed by allodynia/hyperalgesia on days 5–7. (E) CXB7/ByJ mice receiving antisense siRNA exhibit decreasedMOR-1K gene expression
levels in the spinal cord as compared to those receiving sense siRNA. For all behavioral graphs, blue background indicates a decrease in pain sensitivity
(analgesia), and red background indicates an increase in pain sensitivity (allodynia/hyperalgesia). Panels B-D:N = 6-9/group. Data expressed as
mean ± SEM.****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 different from Sham. Panel E: N = 3-4/group. **p<0.01 different from Sense.
doi:10.1371/journal.pone.0135711.g003
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Discussion
Here, we provide the first evidence suggesting that in genetically susceptible animals, MOR-1K
contributes to the development of OIH. Compared to C57BL/6J and 129S6 mice, CXB7/ByJ
mice exhibited the greatest degree of pain following morphine administration alongside
increasedMOR-1K gene expression levels. Reductions inMOR-1K gene expression via sus-
tained delivery of antisense siRNA not only prevented OIH, but also unmasked morphine
analgesia.
The results of this study demonstrate the significance of genetic variability of the mu-opioid
receptor in the development of OIH. Of the three mouse strains, CXB7/ByJ mice exclusively
exhibited increased pain sensitivity, evident immediately following morphine administration.
Their hyperalgesic pain profile also paralleled increasedMOR-1KmRNA transcript levels. For
this reason, we selected this strain to examine the effects ofMOR-1K knockdown using anti-
sense exon 13 siRNA. CXB7/ByJ mice receiving sustained i.t. delivery of antisenseMOR-1K
siRNA failed to develop OIH and instead exhibited morphine analgesia. Sustained delivery of
antisense siRNA significantly reducedMOR-1K gene expression levels within the spinal cord.
Given that i.t. delivery provides direct access to the spinal cord, we hypothesize that MOR-1K
siRNA integrated into primary and secondary order neurons and cleavedMOR-1KmRNA
transcripts, resulting in decreasedMOR-1K gene expression levels.
When examiningMOR-1K gene expression levels in the three mouse strains, we found
that C57BL/6J mice exhibited different gene expression patterns during chronic morphine
administration when compared to CXB7/ByJ mice. On day 1, C57BL/6JMOR-1K gene expres-
sion levels were similar to those of the CXB-7/ByJ mice, but on day 4 their expression levels
decreased 2.4% while those of the CXB-7/ByJ mice increased 2.5%. It is possible thatMOR-1K
gene expression is negatively regulated in C57BL/6J mice and that is why they exhibit opioid-
induced hyperalgesia to a lesser degree than CXB7/ByJ mice. For example, Lu et al provide
evidence of microRNA-103/107 downregulation of mu opioid splice variant MOR-1A [22].
Further research is needed to investigate the possible strain-specific modulators of MOR-1K
expression.
In this study, we observed that, despite a return ofMOR-1K gene expression to baseline lev-
els, C57BL/6J and CXB7/ByJ mice continued to exhibit OIH following morphine cessation
(Fig 2). This persistence of OIH following opioid cessation has also been observed in other pre-
clinical and clinical studies. In mice, administration of antagonists against the 5-HT3 receptor
(5HT3R) [23], N-Methyl-D-aspartate receptor (NMDAR), melanocortin-1 receptor (MC1R)
[24] alongside morphine or beta-2-adrenergic receptor (β2AR) [14] prevent the development
of OIH. In addition, β2AR-deficient mice fail to develop OIH [14]. Clinical studies have also
shown that administration the β2AR antagonist propranolol [25] or NMDAR antagonist keta-
mine [26,27] alongside the fast-acting opioid remifentanil hinders the development of OIH fol-
lowing opioid cessation. Collectively, these findings suggest that MOR-1K may interact with
other receptors, including 5HT3R, NMDAR, MC1R, and β2AR, to initiate and maintain OIH.
The study highlights the impact of MOR-1 splice variants in opioid and pain signaling. To
date, thirty-four MOR-1 splice variants have been identified in mouse, and twenty in human
[5], indicating a significant potential for diversity in MOR-1 signaling. MOR-1 splice variants
other than MOR-1K have been shown to play modulatory roles in opioid signaling. For exam-
ple, Liu et al have demonstrated that splice variant MOR-1D heterodimerizes with the gastrin-
releasing peptide receptor, resulting in signaling that promotes opioid-induced itch [28].
Another MOR-1 splice variant, MOR-1G, has been shown to heterodimerize with the nocicep-
tin receptor ORL-1 to provide a binding site for the novel opioid analgesic 3-iodobenzoyl-6β-
naltrexamide [29]. Along with modulating opioid analgesia and opioid-related side effects,
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MOR-1 splice variants have also been shown to stabilize the canonical receptor at the cell
membrane [30]. These findings demonstrate the influence of splice variants on pain modula-
tion and canonical receptor function. Future research is needed in order to elucidate the func-
tional characteristics of other unexplored MOR-1 splice variants.
Our findings extend previous work examining the effects of genetic variability on opioid
analgesia and hyperalgesia. Results from other animal studies have demonstrated strain-spe-
cific opioid analgesia efficacy [31] and fentanyl-induced hyperalgesia [32]. Likewise, results
from human studies have demonstrated that functional variation in the MOR-1 gene locus reg-
ulates opioid responses. For example, the MOR-1 A118G gene polymorphism, which leads to
reduced MOR signaling [33], is associated with reduced morphine efficacy [34]. More recently,
theMOR-1K rs563649 polymorphism, which results in increasedMOR-1K translation effi-
ciency, has been associated with increased pain sensitivity and blunted morphine efficacy [6].
Combined, these results suggest that genetic susceptibility, particularly in the MOR-1 gene
locus, contributes to diminished opioid efficacy and the development of OIH.
In order to understand the mechanisms whereby MOR-1K contributes to OIH, its expression
patterns and signaling profiles must be defined. At the tissue level, MOR-1K is expressed in
astrocytes within the central nervous system and in perineurial cells within the peripheral ner-
vous system [35], indicating possible influence of glial activation in OIH [4]. At the cellular level,
MOR-1K is normally expressed intracellularly [7], where it may drive Gs-dependent increases in
intracellular cAMP and calcium following active transport or passive diffusion of morphine
across the cell membrane [36,37]. In the presence of β2AR, a GPCR also implicated in OIH [25].
MOR-1K has been shown to relocate to the cellular membrane in vitro [38]. Specifically, the
authors utilized immunofluorescence to show that MOR-1K and β2AR co-localize within the
cell and that both receptors move to the cell membrane. These data suggest the two receptors
interact with one another, perhaps by forming a heterodimer. More in vitro studies, such as co-
immunoprecipitation, are necessary to determine if this is indeed the case. Although its gene
expression and signaling profiles are somewhat established, knowledge onMOR-1K protein
expression is lacking and needs to be defined. Currently available molecular tools, however, are
not selective enough to identify and isolate the MOR-1K protein. Future MOR-1K studies will
benefit from the development of antibodies and ligands that specifically target this splice variant.
IN CONCLUSION, the present study demonstrates a functional role for MOR-1K in a murine
model of OIH. More work is required to determine MOR-1K’s downstream effectors and sig-
naling mechanisms as well as to understand its contribution to individual variability in a more
comprehensive set of opioid responses. Outcomes from present and future studies will help
elucidate the neurobiological mechanisms that drive OIH and, in turn, will inform the develop-
ment of more rational treatment strategies that alleviate clinical pain while reducing OIH risk.
Supporting Information
S1 ARRIVE Checklist. ARRIVE checklist.
(DOCX)
S1 Fig. Sex-dependent responses to mechanical and thermal heat stimuli across the three
strains. Overall, males and females displayed similar behavioral responses to mechanical and
thermal heat stimuli within strains. Female C57BL/6J mice demonstrated (A) increased paw
withdrawal threshold (F(9,140) = 12.20, p<0.0001) and (B) increased responses following repeated
exposure to an innocuous mechanical stimulus (F(9,140) = 14.50, p<0.0001). Panels A-D:N = 7-
8/group. Males are represented in black bars while females are represented by white bars. Data
expressed as mean ± SEM.p<0.0001, p<0.001, p<0.05 different frommales.
(TIF)
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S2 Fig. Raw data illustrating behavioral responses of 129S6, C57BL/6J, and CXB7/ByJ mice
to mechanical and thermal heat stimuli during chronic morphine administration. All three
strains exhibit distinct behavioral differences in (A) paw withdrawal threshold (F(22,516) = 71.94,
p<0.0001, and when assessing responses to the repeated exposure of (B) an innocuous mechani-
cal stimulus (F(22,516) = 35.37, p<0.0001), (C) a noxious mechanical stimulus (F(22,516) = 28.54,
p<0.0001), and (D) a thermal heat stimulus; F(22,516) = 4.214, p<0.0001). Panels A-D:N = 15-
16/group. Data expressed as mean ± SEM.  = different from baseline.
(TIF)
S3 Fig. Raw data illustrating behavioral responses of 129S6, C57BL/6J, and CXB7/ByJ mice
to mechanical and thermal heat stimuli during saline administration. Strains exhibit no sig-
nificant changes from their respective baselines when assessing for (A) paw withdrawal threshold
(F(2,516) = 377.7, p<0.0001), and when assessing responses following repeated exposure to (B) an
innocuous (F(2,516) = 29.08, p<0.0001), or (C) noxious mechanical stimulus (F(2,516) = 1857,
p<0.0001). (D) Unlike 129S6 and C57BL/6J mice, CXB7/ByJ mice exhibited increased responses
to thermal heat stimuli (F(2,516) = 115.2, p<0.0001) starting on day 1 following saline administra-
tion that steadily returned to baseline throughout testing. Panels A-D:N = 15-16/group. Data
expressed as mean ± SEM.  = different from baseline.
(TIF)
S4 Fig. Z-scores ofMOR-1K gene expression levels in discrete tissues of 129S6 mice. Tissue
samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E) thalamus,
(F) hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have similar
MOR-1K gene expression levels in 129S6 mice. Panels A-I: N = 7/group. Data expressed as
Z-score.
(TIF)
S5 Fig. Z-scores ofMOR-1K gene expression levels in discrete brain regions of C57BL/6J
mice. Tissue samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E)
thalamus, (F) hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have
similarMOR-1K gene expression levels in C57BL/6J mice. Panels A-I: N = 7/group. Data
expressed as Z-score.
(TIF)
S6 Fig. Z-scores ofMOR-1K gene expression levels in discrete brain regions of CXB7/ByJ
mice. Tissue samples from (A) spinal cord, (B) medulla, (C) pons, (D) periaqueductal gray, (E)
thalamus, (F) hypothalamus, (G) striatum, (H) nucleus accumbens, and (I) frontal lobe have
similarMOR-1K gene expression levels in CXB7/ByJ mice. Panels A-I: N = 7/group. Data
expressed as Z-score.
(TIF)
S7 Fig. Relative quantification of other exon 11 MOR-1 splice variants (A-C). Chronic mor-
phine administration does not significantly alter the gene expression levels of MOR-1 splice
variants that contain exon 11, exon 14, or exon 16. Panels A-I: N = 7-8/group. Data expressed
as Z-score.
(TIF)
S8 Fig. Sex-dependent behavioral responses to mechanical stimuli across Antisense, Sense,
and Sham mice.Male and female Antisense mice (A-C), Sense mice (D-F), and Sham mice
(G-I) exhibited similar responses to mechanical stimuli within their respective treatment
groups. Panels A-I: N = 3-4/group. Data expressed as mean ± SEM.
(TIF)
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S9 Fig. Raw data illustrate behavioral responses of Antisense, Sense, and Sham mice to
mechanical stimuli during chronic morphine administration. Antisense mice exhibit (A)
lower paw withdrawal threshold, (B) decreased responses to repeated innocuous (C) and nox-
ious stimuli when compared to Sense and Sham mice. Panels A-D: N = 6-9/group. Data
expressed as mean ± SEM.  = different from baseline.
(TIF)
S10 Fig. Raw data illustrate behavioral responses of Antisense, Sense, and Shammice to
mechanical stimuli during saline administration. Antisense, Sense, and Sham mice did not
exhibit behavioral differences from their respective baselines when assessing for (A) paw with-
drawal threshold (F(2,160) = 34.87, p<0.0001), (B) mechanical allodynia (F(2,160) = 45.01,
p<0.0001), (C) mechanical hyperalgesia (F(2,160) = 23.43, p<0.0001) during saline administra-
tion. Panels A-D: N = 6-9/group. Data expressed as mean ± SEM.  = different from baseline.
(TIF)
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